ABN Amro Investment Solutions Acquires 3,387 Shares of Stryker Corporation $SYK

ABN Amro Investment Solutions boosted its position in shares of Stryker Corporation (NYSE:SYK) by 1.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 203,567 shares of the medical technology company’s stock after buying an additional 3,387 shares during the quarter. Stryker accounts for approximately 0.9% of ABN Amro Investment Solutions’ investment portfolio, making the stock its 23rd largest position. ABN Amro Investment Solutions’ holdings in Stryker were worth $66,890,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the 4th quarter worth about $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker in the fourth quarter worth about $27,000. Finally, DJE Kapital AG bought a new stake in Stryker in the fourth quarter worth about $28,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 1.6%

Stryker stock opened at $313.89 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The firm has a market cap of $120.33 billion, a P/E ratio of 36.33, a P/E/G ratio of 2.04 and a beta of 0.77. The business has a fifty day moving average of $313.79 and a two-hundred day moving average of $336.20. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Analyst Ratings Changes

Several research firms have recently weighed in on SYK. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Needham & Company LLC lowered their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Canaccord Genuity Group dropped their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.